Latest1 information on COVID-19
©2022 Stanford Medicine
Trial ID: NCT01463423
Trial of Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)
Jack, Lulu, and Sam Willson Professor and Professor of Radiation Oncology (Radiation Therapy)
Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Professor, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS)
Professor of Radiation Oncology (Radiation Therapy)
- Limited primary non-small cell lung cancers (NSCLC) (ie, graded as T1aN0M0, T1bN0M0,
T2aN0M0, T2bN0M0, or T3N0M0), or metastatic lung tumors with no evidence of
uncontrolled extrathoracic metastases.
- Up to 4 lesions may be considered.
- For a single lesion, the sum of three orthogonal diameters can be no more than 20
- For multiple lesions, no lesion can have a sum of orthogonal diameters greater
than 15 cm.
- Both peripheral and central tumors are accepted for this trial.
- Age ≥ 18 years old
- Patients may be enrolled more than once (eg, for a new tumor lesion)
- Contraindication for radiotherapy
- Pregnant and breastfeeding women are excluded
- If prior radiation therapy, there is no overlap with the prior high dose regions
(EXCEPTION: by approval of the investigators).
radiation: iSABR, 25 Gray in 1 fraction for small peripheral tumors
radiation: iSABR, 50 Gray in 4 fractions for medium peripheral tumors
radiation: iSABR, 54 Gray in 3 fractions for large peripheral tumors
radiation: iSABR, 40 Gray in 4 fractions for small central tumors
radiation: iSABR, 50 Gray in 4 fractions for medium central tumors
radiation: iSABR, 60 Gray in 8 fractions for large central tumors
School of Medicine
300 Pasteur Drive
Stanford, CA 94305